PuSH - Publikationsserver des Helmholtz Zentrums München

Zoellner, A.K.* ; Weiglein, T. ; Hutter, G. ; Zimmermann, Y. ; Cieplik, H.C. ; Hess, G.* ; Dreyling, M.

Temsirolimus acts as additive with bendamustine in aggressive lymphoma.

Ann. Hematol. 95, 403-407 (2015)
DOI PMC
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal role in the control of cell proliferation, survival, and angiogenesis with multiple and frequent dysregulations of this pathway in human tumors. Temsirolimus is an intravenous drug, specifically inhibiting the mTOR pathway. Bendamustine is well known for its clinical activity in indolent non-Hodgkin-lymphoma (NHL) and has lately shown clinical activity in mantle cell lymphoma (MCL). Here, we present a case report of temsirolimus in combination with bendamustine and rituximab leading to a CR in a pretreated male. In addition, our in vitro data underlines the additive and synergistic efficacy in cell growth reduction of temsirolimus combined with bendamustine in MCL cell lines and in DLBCL cell lines. Furthermore, as an underlying mechanism of this additive, effects on cell cycle inhibition and apoptosis induction could be identified.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bendamustine ; Dlbcl ; Mcl ; Temsirolimus; Mantle Cell Lymphoma; Non-hodgkin-lymphoma; 1st-line Treatment; Plus Rituximab; Cycle Arrest; Mtor; Combination; Indolent; Trial; Multicenter
ISSN (print) / ISBN 0939-5555
e-ISSN 1432-0584
Zeitschrift Annals of Hematology
Quellenangaben Band: 95, Heft: 3, Seiten: 403-407 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Functional Epigenetics (IFE)